Home › SEC Filings › Current Report (8-K)
Current Report (8-K)
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| LXFR | 8-K | neutral | 3/10 | Luxfer Holdings filed an 8-K to voluntarily supplement its definitive proxy statement with additional disclosures relate | Oct 26, 2026 |
| WST | 8-K | neutral | 4/10 | West Pharmaceutical Services entered into a new $950 million unsecured credit agreement on October 26, 2026, consisting | Oct 26, 2026 |
| VENU | 8-K | neutral | 5/10 | Venu Holding Corp entered into an amended and restated development agreement with the City of McKinney, Texas, and its e | Oct 26, 2026 |
| GRBK | 8-K | neutral | 2/10 | Green Brick Partners appointed its Co-CEO, Jed Dolson, to the Board of Directors, effective October 22, 2026, expanding | Oct 26, 2026 |
| CYCU | 8-K | neutral | 2/10 | Cycurion disclosed that director Peter R. Ginsberg stepped down from all board committees due to independence concerns a | Oct 26, 2026 |
| EQ | 8-K | bearish | 6/10 | Equillium dosed the first subject in a Phase 1 trial of EQ504, triggering a $20 million milestone closing under its Augu | Oct 26, 2026 |
| ONCO | 8-K | neutral | 3/10 | Onconetix announced a second 1-for-10 reverse stock split, effective November 6, 2026, reducing outstanding shares from | Oct 26, 2026 |
| BRO | 8-K | bearish | 5/10 | Brown & Brown reported Q3 2026 total revenues of $1.725B, up 7.4% YoY, but GAAP diluted EPS fell 1.5% to $0.67. Adjusted | Oct 26, 2026 |
| NE | 8-K | bearish | 6/10 | Noble Corp plc reported Q3 2026 results with a GAAP net loss of $117 million (diluted EPS -$0.73) versus a consensus est | Oct 26, 2026 |
| NMFC | 8-K | neutral | 3/10 | New Mountain Finance Corp extended its existing stock repurchase program by one year, from December 31, 2026 to December | Oct 26, 2026 |
| GOAI | 8-K | bearish | 5/10 | Eva Live Inc. received a notice from Streeterville Capital asserting that the company's October 2026 transaction with Du | Oct 26, 2026 |
| MEDS | 8-K | bearish | 6/10 | DataMEDS AI entered a non-binding second amended and restated letter of intent to acquire QLPM intellectual property fro | Oct 26, 2026 |
| XBP | 8-K | neutral | 4/10 | Par Chadha, Chairman of the Board and beneficial owner of 25.93% of XBP stock, notified the company he will not stand fo | Oct 26, 2026 |
| YHNA | 8-K | bearish | 8/10 | YHN Acquisition I received a final delisting determination from Nasdaq on October 21, 2026, after failing to regain comp | Oct 26, 2026 |
| BRBS | 8-K | bearish | 6/10 | Blue Ridge Bankshares reported a Q3 2026 net loss of $4.2 million ($0.05 per share), compared to a net loss of $1.3 mill | Oct 26, 2026 |
| ZEO | 8-K | bearish | 7/10 | Zeo Energy Corp. received a 180-day extension from Nasdaq, until April 19, 2027, to regain compliance with the $1.00 min | Oct 26, 2026 |
| NUE | 8-K | bullish | 6/10 | Nucor reported Q3 2026 net earnings of $1.32 billion ($5.80 per diluted share) on net sales of $11.25 billion, compared | Oct 26, 2026 |
| RLYB | 8-K | neutral | 5/10 | Rallybio Corp's board declared a special cash distribution of approximately $82.7 million ($13.56 per share) to stockhol | Oct 26, 2026 |
| SXI | 8-K | neutral | 2/10 | Standex International Corporation announced the planned retirement of director B. Joanne Edwards effective January 1, 20 | Oct 26, 2026 |
| GNVR | 8-K | neutral | 3/10 | Genvor entered into an Intellectual Property Assignment Agreement with founder and CSO Dr. Jesse Jaynes, confirming the | Oct 26, 2026 |
| SORN | 8-K | neutral | 2/10 | Soren Acquisition Corp. (SORN) announced a planned leadership transition: three directors (Spencer Gerrol, Charles N. Ka | Oct 26, 2026 |
| MIRM | 8-K | bullish | 6/10 | Mirum Pharmaceuticals announced positive Phase 3 PROGRESS Cohort 2 results for ATEBRIOZ (zilurgisertib) in pediatric FOP | Oct 26, 2026 |
| KNTK | 8-K | neutral | 3/10 | Kinetik Holdings subsidiary EagleClaw Midstream Ventures (ECMV) and Energy Transfer (ET) settled a dispute over the expi | Oct 26, 2026 |
| LGVN | 8-K | neutral | 5/10 | Longeveron announced updated results from its ELPIS II Phase 2b trial of laromestrocel in HLHS. The trial missed the pri | Oct 26, 2026 |
| EAF | 8-K/A | bearish | 5/10 | GrafTech International filed an amendment to its August 31, 2026 8-K to provide finalized estimates of non-cash charges | Oct 26, 2026 |
| SUPN | 8-K | neutral | 2/10 | Supernus Pharmaceuticals terminated its uncommitted demand revolving UBS Credit Line on October 20, 2026, in anticipatio | Oct 26, 2026 |
| FLXS | 8-K | bearish | 5/10 | Flexsteel reported fiscal Q1 2027 net sales of $114.0M (+3.2% YoY), in line with the $112.7M consensus, but GAAP diluted | Oct 26, 2026 |
| CMCO | 8-K | neutral | 2/10 | Columbus McKinnon Corp filed an 8-K announcing that its Board of Directors declared a regular quarterly dividend of $0.0 | Oct 26, 2026 |
| CVSI | 8-K | neutral | 2/10 | CV Sciences settled its JAMS arbitration against former legal counsel, receiving $500,000 and mutually releasing all cla | Oct 26, 2026 |
| CPIX | 8-K | neutral | 5/10 | Cumberland Pharmaceuticals announced plans to submit a New Drug Application (NDA) to the FDA for ifetroban as a treatmen | Oct 26, 2026 |